» Articles » PMID: 17627610

Comparable Potency of IFNalpha2 and IFNbeta on Immediate JAK/STAT Activation but Differential Down-regulation of IFNAR2

Overview
Journal Biochem J
Specialty Biochemistry
Date 2007 Jul 14
PMID 17627610
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Type I IFNs (interferons) (IFNalpha/beta) form a family of related cytokines that control a variety of cellular functions through binding to a receptor composed of IFNAR (IFNalpha receptor subunit) 1 and 2. Among type I IFNs, the alpha2 and beta subtypes exhibit a large difference in their binding affinities to IFNAR1, and it was suggested that high concentrations of IFNAR1 may compensate for its low intrinsic binding affinity for IFNalpha2. We tested whether receptor-proximal signalling events are sensitive to IFNAR1 surface concentration by investigating the relationship between relative IFNAR1/IFNAR2 surface levels and IFNalpha2 and IFNbeta signalling potencies in several cell lines. For this, we monitored the activation profile of JAK (Janus kinase)/STAT (signal transducer and activator of transcription) proteins, measured basal and ligand-induced surface decay of each receptor subunit and tested the effect of variable IFNAR1 levels on IFNalpha2 signalling potency. Our data show that the cell-surface IFNAR1 level is indeed a limiting factor for assembly of the functional complex, but an increased concentration of it does not translate into an IFNalpha/beta differential JAK/STAT signalling nor does it change the dynamics of the engaged receptor. Importantly, however, our data highlight a differential effect upon routing of IFNAR2. Following binding of IFNalpha2, IFNAR2 is internalized, but, instead of being routed towards degradation as it is when complexed to IFNbeta, it recycles back to the cell surface. These observations suggest strongly that the stability and the intracellular lifetime of the ternary complex account for the differential control of IFNAR2. Moreover, the present study opens up the attractive possibility that endosomal-initiated signalling may contribute to IFNalpha/beta differential bioactivities.

Citing Articles

Cloning and Functional Characterization of Novel Human Neutralizing Anti-IFN-α and Anti-IFN-β Antibodies.

Papasavvas E, Lu L, Fair M, Oliva I, Cassel J, Majumdar S J Immunol. 2024; 213(6):808-822.

PMID: 39109927 PMC: 11575944. DOI: 10.4049/jimmunol.2400265.


STAM and Hrs interact sequentially with IFN-α Receptor to control spatiotemporal JAK-STAT endosomal activation.

Zanin N, Viaris de Lesegno C, Podkalicka J, Meyer T, Gonzalez Troncoso P, Bun P Nat Cell Biol. 2023; 25(3):425-438.

PMID: 36797476 DOI: 10.1038/s41556-022-01085-6.


Anti-IFN-α/-ω neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity.

Frasca F, Scordio M, Santinelli L, Gabriele L, Gandini O, Criniti A Eur J Immunol. 2022; 52(7):1120-1128.

PMID: 35419822 PMC: 9087404. DOI: 10.1002/eji.202249824.


Molecular and cellular factors determining the functional pleiotropy of cytokines.

McFarlane A, Pohler E, Moraga I FEBS J. 2022; 290(10):2525-2552.

PMID: 35246947 PMC: 10952290. DOI: 10.1111/febs.16420.


Determinants of Ligand Specificity and Functional Plasticity in Type I Interferon Signaling.

Kirby D, Parmar B, Fathi S, Marwah S, Nayak C, Cherepanov V Front Immunol. 2021; 12:748423.

PMID: 34691060 PMC: 8529159. DOI: 10.3389/fimmu.2021.748423.


References
1.
Di Guglielmo G, Le Roy C, Goodfellow A, Wrana J . Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol. 2003; 5(5):410-21. DOI: 10.1038/ncb975. View

2.
Ragimbeau J, Dondi E, Alcover A, Eid P, Uze G, Pellegrini S . The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. EMBO J. 2003; 22(3):537-47. PMC: 140723. DOI: 10.1093/emboj/cdg038. View

3.
Kumar K, Tang W, Ravindranath A, Clark W, Croze E, Fuchs S . SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. EMBO J. 2003; 22(20):5480-90. PMC: 213778. DOI: 10.1093/emboj/cdg524. View

4.
Teis D, Huber L . The odd couple: signal transduction and endocytosis. Cell Mol Life Sci. 2003; 60(10):2020-33. PMC: 11138817. DOI: 10.1007/s00018-003-3010-2. View

5.
Langer J, Cutrone E, Kotenko S . The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions. Cytokine Growth Factor Rev. 2004; 15(1):33-48. DOI: 10.1016/j.cytogfr.2003.10.001. View